ReviewInternal medicine (Tokyo, Japan)2025
High-grade and Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas with STK11 Aberration Having Undergone Pancreatic Resection Three Times for Metachronous Intrapancreatic Recurrences: A Case Report and Review of the Literature.
Review in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 56-year-old woman with high-grade or invasive intraductal papillary mucinous neoplasm (IPMN) underwent 3 pancreatic surgeries for initial and recurrent IPMN lesions. Immunostaining and genetic analyses of all lesions revealed a consistent mutation in KRAS and loss of serine/threonine kinase 11 (STK11), indicating the same origin of these lesions and the possibility of intraductal dissemination. Other immunostaining findings, such as mucin expression and a high Ki-67 labeling index, were consistent among all the lesions and supported their malignant potential. IPMNs with loss of STK11 may benefit from tailored follow-up of the remnant pancreas due to their high likelihood of recurrence through intraductal spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.